Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 8,510,000 shares, an increase of 28.5% from the January 31st total of 6,620,000 shares. Based on an average daily volume of 13,950,000 shares, the short-interest ratio is currently 0.6 days. Approximately 11.2% of the company's shares are short sold.

Invivyd Stock Performance

IVVD traded down $0.02 on Friday, reaching $1.01. 1,341,351 shares of the company's stock were exchanged, compared to its average volume of 20,580,926. The company's 50 day moving average is $0.92 and its 200-day moving average is $0.88. The company has a market cap of $120.81 million, a price-to-earnings ratio of -0.52 and a beta of 0.09. Invivyd has a twelve month low of $0.35 and a twelve month high of $4.74.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Invivyd in a research note on Monday, February 24th. Finally, Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $7.89.

Remove Ads

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of the company's stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $0.61, for a total transaction of $91,500.00. Following the completion of the transaction, the director now owns 4,538,079 shares of the company's stock, valued at $2,768,228.19. This represents a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 816,466 shares of company stock worth $423,214. Corporate insiders own 17.90% of the company's stock.

Institutional Trading of Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the business. Proficio Capital Partners LLC acquired a new stake in Invivyd during the 3rd quarter worth approximately $27,000. Jane Street Group LLC increased its position in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after purchasing an additional 87,358 shares in the last quarter. Barclays PLC increased its position in Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after purchasing an additional 9,207 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Invivyd during the 4th quarter worth approximately $74,000. Finally, JPMorgan Chase & Co. increased its position in Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after purchasing an additional 222,375 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.